Skip to content

Effects of NB-UVB Combined with calcipotriol on Serum 1,25(OH)2D3, IL-37 and IFN-? in Patients with Psoriasis Vulgaris

Effects of NB-UVB Combined with calcipotriol on Serum 1,25(OH)2D3, IL-37 and IFN-? in Patients with Psoriasis Vulgaris

Status
Active, not recruiting
Phases
Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900020965
Enrollment
Unknown
Registered
2019-01-23
Start date
2019-01-28
Completion date
Unknown
Last updated
2019-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Interventions

experimental group:narrow-band ultraviolet B combined with calcipotriol
control group:none

Sponsors

Affiliated Hospital of Xuzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 - 65 years old, the condition in a stable period; 2. Psoriasis affected area ( BSA ) is 3 - 50 % of body surface area; PASI score is 3 - 10; 3. No systemic or local treatment was received two weeks before the test; 4. Approved by the Ethics Committee and signed with informed consent.

Exclusion criteria

Exclusion criteria: 1. Within 8 weeks, he has systematically used Avi A drugs, glucocorticoids, immunosuppressants, phototherapy and other treatments for psoriasis, and received local anti-psoriasis treatment within 4 weeks; 2. Patients suffering from serious visceral diseases such as heart, liver and kidney; 3. Patients with immune deficiency; 4. Hypercalcemia patients; 5. Women during pregnancy, lactation and pregnancy preparation; 6. Allergic to external drugs or ultraviolet rays; 7. There is a history of other skin diseases ( e.g. eczema, neurodermatitis, actinic keratosis, erythema multiforme, skin lymphoma).

Design outcomes

Primary

MeasureTime frame
PASI;

Secondary

MeasureTime frame
VAS;DLQI;

Countries

China

Contacts

Public ContactWei Zhiping

Affiliated Hospital of Xuzhou Medical University

xzwzp1961@aliyun.com+86 18052268255

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026